Sexually Transmitted Diseases

Today, the FDA approved the long-acting HIV treatment Cabenuva (cabotegravir and rilpivirine dually administered) for virologically suppressed adolescents 12 years and older.

Tori Pipak, a physician assistant at Allegheny Health Network’s Positive Health Clinic, details the comprehensive services the clinic provides to people living with HIV.

With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.

Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.

The study authors wrote that few people who initiate tenofovir disoproxil fumarate-based oral PrEP rarely experience clinically significant kidney impairment.

A new virtual program aims to train clinicians and other providers on terminology and how to engage patients in effective dialogue and counseling.

The study authors suggest further research and investment to identify areas of support for individuals at the highest risk of poor outcomes.

With 3 vaccine candidates, the National Institutes of Health (NIH) is launching one of the first trials to examine the safety and efficacy of mRNA technology in HIV vaccination.

This findings present an opportunity for countries to critically review testing approaches to develop specific targeted HIV testing.

The Affordable Care Act can remove financial barriers and increase access to PrEP, the study authors said.

The federal agency cited chemistry manufacturing and controls issues with vials.

The FDA approved the One Male Condom as the first condom approved and proven to protect against STIs and HIV during anal sex.

A review of treatment modalities for this patient population.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.

Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

A study found 5% of German test-site visitors had a sexually transmitted infection. STI rates, including HIV incidence, were highest among men who have sex with men.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Black patients enrolled in an LA Medical Care Coordination program were less likely to achieve viral suppression than HIV-positive people of other races.

Though HIV diagnoses have declined overall, new infections still disproportionately occur in certain racial, ethic, gender, and geographic populations.

Investigators found a couple of different factors for this phenomenon.

In a global cohort, more than 1 in 3 people living with HIV reported functional impairments. Functional impairment was more common among HIV-positive people who were older, Black, or female.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

Investigators looked to see if this population might be candidates for this form of HIV prevention.

One study presented at CROI 2022 found that HIV PrEP awareness increased among Latinx/Hispanic men who have sex with men, but usage has remained relatively stable for several years.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

Investigators modeled what a long-acting injectable HIV prevention medication would have to cost in order for it to be justified when compared to generic, oral PrEP for HIV patients and transmission prevention.

The VB variant likely originated in the late 1990s, and if left untreated, is more transmissible and deadly than prior HIV strains.